Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
| ▸ | GABRE | P78334 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicuculline SCHEMBL28213750 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL16320040 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29617593 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL8222 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5481014 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29366341 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29652597 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL7913545 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5783586 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL2532354 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | claimed |
| US-20260069680-A1 | HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF | CITY OF HOPE (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | BLUEBIRD BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12502562-B2 | Human iPSC-derived brain organoids and uses thereof | CITY OF HOPE (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250290097-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2025-09-18 | — | — | US | disclosed |
| US-20250288546-A1 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | NEUROPRO THERAPEUTICS INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250235501-A1 | Methods and Compositions for Treating or Preventing Neurological Injury or Neurological Disorders | UNIVERSITY OF CONNECTICUT (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4572748-A1 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | NEUROPRO THERAPEUTICS, INC. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12337173-B2 | Devices, systems, and methods for promoting voiding in subjects with underactive bladders | DUKE UNIVERSITY (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | ORCHARD THERAPEUTICS EUROPE LTD (GB) | 2025-05-01 | — | — | US | disclosed |
| US-20220160788-A1 | BIFUNCTIONAL VECTORS ALLOWING BCL11A SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF B-HEMOGLOBINOPATHIES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-05-26 | — | — | US | disclosed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | disclosed |
| EP-2695618-B2 | Pharmaceutical composition comprising lacosamide and levetiracetam for use in the treatment of epilepsy | UCB PHARMA GMBH (DE) | 2022-05-11 | — | — | EP | disclosed |
| US-11326183-B2 | VCN enhancer compositions and methods of using the same | BLUEBIRD BIO, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2022063754-A1 | BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-03-31 | — | — | WO | disclosed |
| US-20220088225-A1 | VIRAL TRANSDUCTION USING POLOXAMINES | REVVITY GENE DELIVERY GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| EP-3656848-B1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | BLUEBIRD BIO INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11261441-B2 | Vectors and compositions for treating hemoglobinopathies | BLUEBIRD BIO, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| WO-2022036179-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEREDITARY ANGIOEDEMA | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | PTGES2, POLN, HPGDS | CYP3A4 3042/4885CYP2C9 3031/4885CYP2C19 1691/4885 |
| US-20250288546-A1 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | GAP43, GABRB3, GABRB2 | CYP3A4 4249/4885CYP2C9 4309/4885CYP2C19 3918/4885 |
| US-20220088225-A1 | VIRAL TRANSDUCTION USING POLOXAMINES | POLB, POLR2E, POLRMT | CYP3A4 3912/4885CYP2C9 4456/4885CYP2C19 4601/4885 |
| US-20260069680-A1 | HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF | PDGFRA, PDGFRB, PDGFA | CYP3A4 3174/4885CYP2C9 4237/4885CYP2C19 3132/4885 |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | CD4, CD74, HLA-DRB1 | CYP3A4 4347/4885CYP2C9 4194/4885CYP2C19 4428/4885 |
| US-20220160788-A1 | BIFUNCTIONAL VECTORS ALLOWING BCL11A SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF B-HEMOGLOBINOPATHIES | HBG1, HBB, HBG2 | CYP3A4 4492/4885CYP2C9 4669/4885CYP2C19 4788/4885 |
| US-20250290097-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | PHAX, CD44, HCLS1 | CYP3A4 4481/4885CYP2C9 4088/4885CYP2C19 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.